Search Results

Your search for The ASCO Post matches 7936 pages

Showing 1 - 50

hematologic malignancies

Adoptive T-Cell Therapy for Progressive Multifocal Leukoencephalopathy

An emerging treatment known as adoptive T-cell therapy has proven effective in a phase II clinical trial for treating progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer and other diseases in which the immune...

Established, Modifiable Cancer Risk Factors

According to a new American Cancer Society report published by Gapstur et al in CA: A Cancer Journal for Clinicians, the highest priority in a national cancer control plan is the expansion of tobacco control—the intervention with the largest potential health benefits. This report is the...

FDA Approves Talazoparib for Deleterious Germline BRCA-Mutated HER2-Negative Locally Advanced or Metastatic Breast Cancer

On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer....

skin cancer

Small Study of Neoadjuvant Combination Checkpoint Blockade in High-Risk Stage III Melanoma

Neoadjuvant combination checkpoint blockade showed activity among patients with high-risk stage III melanoma in a small study. However, a high incidence of side effects caused the trial to be closed early. These results were published by Amaria et al in Nature Medicine. The phase II...

FDA Accepts New Drug Application, Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has accepted a new drug application seeking accelerated approval for selinexor, a first-in-class, oral selective inhibitor of nuclear export (SINE) compound, as a new treatment for patients with pentarefractory multiple myeloma. The FDA...

ESMO 2018: Patients With Breast Cancer Use Twitter as a Nonmedical Forum to Share Experiences

Twitter is a place where many patients with cancer go to share and discuss their experiences of the disease, according to a recent exploratory study to be presented by Sánchez-Bayona et al at the European Society for Medical Oncology (ESMO) 2018 Congress (360P_PR). The...

ESMO 2018: Precision Cancer Care Moves to Community Setting

Nearly 1 in 4 patients with advanced cancer treated at a community practice cancer network in the United States received innovative drugs matched to DNA mutations in their tumors. These results, to be reported by Alvarez et al at the European Society for Medical Oncology (ESMO) 2018 Congress...

Estradiol as Potential Treatment for Subset of Triple-Negative Breast Cancers

Mayo Clinic researchers have identified estradiol as a potential new treatment for a subset of women with triple-negative breast cancer. Their findings were published by Reese et al in the Proceedings of the National Academy of Sciences of the United States of America. “Triple-negative...

breast cancer
issues in oncology

Report Examines Shortages of Oncologists, Variation in Cancer Rates

Doximity has released a new study detailing a concerning trend that could potentially impact cancer care in the United States. Doximity researchers examined retirement trends, percentage of state-trained specialists, and prevalence of breast cancer on a city-by-city basis. The report is the...

Report Outlines Cancer Risk Among Hispanics/Latinos in the United States

The cancer burden in Puerto Rico, a U.S. territory with a 99% Hispanic population, is substantially different from that of Hispanics in the continental United States, according to Cancer Statistics for Hispanics/Latinos, 2018. The report, published every 3 years, found that men in Puerto Rico...

CHEST 2018: Adherence to Annual Lung Cancer Screening Needs Improvement

A study from the Thoracic Oncology Research Group (TORG), Division of Pulmonary Critical Care, Medical University of South Carolina, aimed to examine the adherence to annual low-dose computed tomography (LDCT) screening after baseline LDCT within the Veteran Health Administration Lung Cancer...

A Pathologic Fascination With Humanity

The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...

Johns Hopkins Radiation Oncology Pioneer, Moody Wharam, Jr, MD, Dies at 77

MOODY WHARAM, JR, MD, Professor Emeritus of Radiation Oncology and Molecular Radiation Sciences and former Willard and Lillian Hackerman Professor of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center, died on August 10 at the age of 77. Dr. Wharam specialized in the treatment of...

Eva Koziolek, DSc, PhD, Awarded First Free Me From Lung Cancer–IASLC Joint Fellowship Award

FREE ME FROM LUNG CANCER (FMFLC) and the International Association for the Study of Lung Cancer (IASLC) have announced the first-ever winner of the FMFLC-IASLC Foundation Joint Fellowship Award for the Early Detection of Lung Cancer. The FMFLC-IASLC Joint Fellowship Award supports novel,...

breast cancer

Living a Purposeful Life Is My Revenge on Cancer

There is a lot of breast cancer in my family history. My mother was diagnosed with the disease at 44, and my paternal grandmother died of breast cancer when she was just 33, so I’ve always been diligent about performing breast self-exams— often weekly—to ensure that if I did get breast cancer, it...

Association of Community Cancer Centers Grants 2018 Innovator Awards

THE ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC) has chosen seven cancer centers nationwide to receive 2018 ACCC Innovator Awards. Now in its 8th year, the Innovator Awards recognize ACCC member programs that have created solutions to challenges commonly faced by cancer programs and practices as...

Learning to Listen and Returning to the Art of Medicine

Bernard Lown, MD, was born in Lithuania, the son of a rabbi. He immigrated to the United States at the age of 14, where his scientific precocity bloomed. After attaining his medical degree from John Hopkins University School of Medicine, he pursued his passion of raising international awareness of...

On Aging and the Wellness Industry

Only a few centuries ago, the major source of moral and scientific authority in Western culture was religion, which requires trusting one of numerous supernatural deities. However, the presumption that medicine is based on evidence-based and peer-reviewed science is what gives it authority in...

Charles Swanton, PhD, FRCP, Receives IASLC Paul A. Bunn, Jr, Scientific Award

CHARLES SWANTON, PhD, FRCP, of The Francis Crick Institute, London, was recognized by the International Association for the Study of Lung Cancer (IASLC) at the 2018 IASLC World Conference on Lung Cancer with the Paul A. Bunn, Jr, Scientific Award, honoring his lifetime achievements in scientific...


James Allison, PhD, and Tasuku Honjo, MD, PhD, Win 2018 Nobel Prize in Physiology or Medicine

JAMES ALLISON, PHD, Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and Tasuku Honjo, MD, PhD, Distinguished Professor at the Kyoto University Institute for Advanced Study and Professor of Immunology and Genomic Medicine ...

issues in oncology
palliative care

Closing the Gender Divide in Preference for Palliative Care

Eight years ago, a survey of the preferences of Dutch patients with cancer for health care found that while gender was one aspect influencing how men and women approach cancer care, it was the most important, with men, generally, regarding most care aspects as less important than women. The study...

lung cancer

FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer

ON SEPTEMBER 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...

solid tumors
issues in oncology

New Techniques in Intraoperative-Guided Imagery May Enhance Outcomes in Patients With Cancer

Primary treatment of most solid tumors includes surgical excision or radiation therapy, both of which require precise anatomic localization of the tumor as well as surrounding tissue and organs. If the targeting is too broad, unnecessary morbidity may occur to nearby structures, along with the...

hematologic malignancies

FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory Hematologic Malignancies

ON SEPTEMBER 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib (Copiktra) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib also received accelerated...

Cleveland Clinic Researchers Receive NIH Grant to Study Cancer-Associated Thrombosis

THE NATIONAL Heart, Lung, and Blood Institute has awarded a $4.7 million grant to the Cleveland Clinic to study the prevention of cancer-associated thrombosis. The 5-year grant supports the creation of a new risk assessment tool to better predict patients with cancer who have a higher probability...

Pasi A. Jänne, MD, PhD, Receives ESMO Translational Research Award

THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has chosen Pasi A. Jänne, MD, PhD, to receive the ESMO Translational Research Award for his research contributions in lung cancer. Dr. Jänne is Director of the Lowe Center for Thoracic Oncology and Director of the Belfer Center for Applied Cancer...

ESMO Recognizes Tony S. Mok, MD, FRCPC, FASCO, With Lifetime Achievement Award

THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has recognized Tony S. Mok, MD, FRCPC, FASCO, with the ESMO Lifetime Achievement Award for his contributions in lung cancer. Dr. Mok, who is a Li Shu Fan Medical Foundation Endowed Professor and Chairman of the Department of Clinical Oncology at the ...

prostate cancer
issues in oncology

PCF Releases First National Report on Public Perception of Prostate Cancer in the United States

The Prostate Cancer Foundation (PCF) recently released the results of its first national public awareness report about risks, actions, and attitudes toward prostate cancer in the PCF 3P Report 2018: Public Perception of Prostate Cancer. Each year, even though more than three million men in...

skin cancer

Results From ECHELON-2: Brentuximab Vedotin in CD30-Expressing Peripheral T-Cell Lymphoma

The phase III ECHELON-2 clinical trial has met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) with brentuximab vedotin (Adcetris) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide,...

Early PSA Testing Could Help Predict Prostate Cancer Among Black Men

In a study published by Preston et al in European Urology, researchers demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between 40 and 60 years old may predict the future development of prostate cancer for years after testing. The study builds on ...

issues in oncology
symptom management

Small Study Shows Fecal Microbiota Transplantation May Help Restore Beneficial Bacteria in Patients With Cancer

Researchers have shown that autologous fecal microbiota transplantation may be a safe and effective way to help replenish beneficial gut bacteria in patients with cancer who require intense antibiotics during allogeneic hematopoietic stem cell transplantation. Their findings were published by Taur...

FDA Approves Expanded Use of Gardasil 9 to Include Individuals Aged 27 to 45

The U.S. Food and Drug Administration (FDA) has approved a supplemental application for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil 9), expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and...

FDA Grants Breakthrough Therapy Designation to Rucaparib in BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to rucaparib (Rubraca) monotherapy for the treatment of adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who have received at least one prior androgen...

ASCP, CAP, and ASH Invite Public Comment on Lymphoma Guideline

With a focus on the pathology aspects of diagnosing lymphoma, the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) are collaborating to develop an evidence-based clinical practice guideline for the workup of...

colorectal cancer
issues in oncology

Sex-Linked Differences in Cancer May Identify Specific Genetic Drivers, Predict Responses to Treatment

Analysis of male- and female-derived tumor samples revealed differences in prognostic biomarkers, genes that drive cancer, and in regulation of key pathways that may predict responses to treatment, according to results published in two studies in Cancer Research, one by Li et al and the other...

head and neck cancer

DNA Vaccine Leads to Immune Responses in HPV-Related Head and Neck Cancer in Small Study

A therapeutic vaccine may boost antibodies and T cells, helping them infiltrate human papillomavirus (HPV)-related head and neck cancer tumors. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with...

multiple myeloma

FDA Authorizes First Next-Generation Sequencing–Based Test to Detect Minimal Residual Disease in B-Cell ALL or Multiple Myeloma

The U.S. Food and Drug Administration (FDA) recently permitted marketing of the ClonoSEQ assay, a next-generation sequencing–based test for minimal residual disease in patients with B-cell acute lymphoblastic leukemia (ALL) or multiple myeloma. “At the FDA, we’re continuing to...

lung cancer
pain management

Study Shows Invasive Lung Cancer Surgery Can Lead to Long-Term Opioid Use

Patients treated with more invasive surgical techniques for early-stage non–small cell lung cancer (NSCLC) are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery ...

gynecologic cancers

Addition of a CTLA-4–Targeted Therapy to a Checkpoint Inhibitor in Ovarian Cancer

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab (Yervoy), a monoclonal antibody that targets the protein receptor cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), to a regimen with the checkpoint inhibitor nivolumab (Opdivo) could improve response ...

breast cancer

More to Learn About Using PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation

Germline mutations in the breast cancer–susceptibility genes 1 and 2 (BRCA1/2) increase the risk for cancer due to an inability to repair DNA double-strand breaks, and about 5% of patients with unselected breast cancer carry a germline BRCA mutation.1 These DNA repair–deficient tumors are...

issues in oncology

Monika K. Krzyzanowska, MD, MPH, on Quality Improvement: Avoiding the Pitfalls

Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre, summarized the Keynote Lecture, including the points that clinicians should carefully plan their quality improvement projects, understand the barriers to quality, and ensure their efforts are sustainable.

issues in oncology
solid tumors

Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care

Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.

supportive care

Jeremy Warner, MD, on Patient Navigation: Weathering the Storm of Cancer Care

Jeremy Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses the ways in which patient navigators affect cancer care and how patients benefit.

thyroid cancer

Lauren P. Wallner, PhD, MPH, on Thyroid Cancer: Reducing Overtreatment With Radioactive Iodine

Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, ...

hematologic malignancies

Targeting CCR4 in Cutaneous T-Cell Lymphoma: The MAVORIC Trial

The C-C chemokine receptor 4 (CCR4) is predominantly expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells.1 Under physiologic conditions and in response to its ligands, CCL17 (TARC) and CCL22 (MDC), CCR4 promotes T-cell migration to the skin.2 Of note, CCR4 is highly expressed in...

issues in oncology
symptom management
pain management

Angela M. Stover, PhD, on Patient-Reported Symptoms: Results From the STAR and PRO-TECT Trials

Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses study findings on ways to alert clinicians when patients signal symptoms such as pain or diarrhea that may be cause for concern (Abstract 158).

issues in oncology

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Simron Singh, MD, MPH, of Sunnybrook Health Sciences Centre, discusses initial results of his data on a new patient experience measurement strategy used at Cancer Care Ontario.

issues in oncology
pain management

Jay B. Shah, MD, on Reducing Opioid Use After Urologic Oncology Surgery

Jay B. Shah, MD, of Stanford University, discusses the role that surgeons can play as gatekeepers to the opioid epidemic, including the view that complex cancer operations can be performed with little to no opioid use (Abstract 269).

issues in oncology
cost of care

Aaron Lyss, MBA, on Getting the Highest-Value Quality Intervention

Aaron Lyss, MBA, of Tennessee Oncology, discusses ways that clinicians and patients can employ the most cost- and treatment-effective measures, clinical trials, and incident learning systems.

Lisa Newman, MD, MPH, FACS, FASCO, Appointed Chief of Breast Surgery at NewYork-Presbyterian

Lisa Newman, MD, MPH, FACS, FASCO, breast surgeon and researcher, has been appointed Chief of the Section of Breast Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine. In her new role, which began at the end of August, Dr. Newman will lead multidisciplinary...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.